More Competitive Salaries Will Improve FDA/Industry Interactions – Crawford
This article was originally published in The Gray Sheet
Executive Summary
FDA staff communications to industry will be more in synch as employee retention rates stabilize because of improvements to salary structure, according to Acting Commissioner Lester Crawford, PhD
You may also be interested in...
FDA personnel retention
Annual turnover rate of 8% among employees indicates that morale at the agency is improving, FDA Deputy Commissioner Lester Crawford tells AdvaMed attendees. "We believe that traditionally and historically about an 8% turnover of personnel on an annual basis is a helpful thing for FDA," he said, noting, "it would be very difficult to manage any material changes in the personnel profile at FDA if we had no turnover." However, if the agency experienced "20-30% turnover every year, that would also be virtually unmanageable," he pointed out. One way FDA is able to maintain key personnel is through a program that allows the agency to forgive student loans of up to $40,000 for medical officers and give them a signing bonus of up to 25% of their base salary, Crawford explained. In terms of recruiting, the agency is "very competitive in the Washington, [D.C.] area," he opined...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.